Increased risk of anal squamous cell carcinoma in HIV-positive men with prior HBV infection

Details

• Alternative Title:
  AIDS
• Personal Author:
  Aldersley, Jordan ; Lorenz, David R. ; Misra, Vikas ; Uno, Hajime ; Gabuzda, Dana
• Description:
  Objective(s):
  
  HIV-positive individuals have elevated rates of anal squamous cell carcinoma (SCC), and sexually transmitted infections with its causative agent, high-risk human papillomavirus, and other oncoviruses including hepatitis B virus (HBV). HBV infection can cause liver cancer, and has been associated with increased risk of some extra-hepatic cancers including biliary tract cancer, pancreatic cancer, and non-Hodgkin lymphoma. Whether HBV is associated with anal SCC risk is unknown.
  
  Design:
  
  Prospective study of anal SCC risk in HIV-positive and -negative men who have sex with men (MSM) in the Multicenter AIDS Cohort Study from 1984–2014.
  
  Methods:
  
  Poisson regression models were used to examine the association between past or current HBV infection (positive tests for HBV core antibodies, surface antigen, and/or DNA) and anal SCC risk.
  
  Results:
  
  We observed 53 cases of anal SCC among 5,298 participants with 79,334 person-years follow-up. Among HIV-positive men, past or current HBV infection was associated with anal SCC risk in models adjusted for age, CD4+ cell counts, HAART use, and other risk factors (incidence rate ratio [IRR], 95% confidence interval [CI] 3.15, 1.27–7.82). Additional risk factors included immunological parameters one and six years prior to diagnosis (IRR, 95% CI 2.45, 1.31–4.58 and 2.44, 1.3–4.59 for CD4+ counts <500 cells/μl; 2.43, 1.34–4.42 and 2.77, 1.5–5.11 for CD4:CD8 ratios <0.5, respectively). Among HIV-negative men, IRR for prior HBV and anal SCC risk was similar, but not significant due to small number of cases.
  
  Conclusions:
  
  HIV-positive MSM with prior HBV infection have increased anal SCC risk. This population may benefit from screening.
  
  
• Subjects:
  Anal Cancer Article Cancer Epidemiology Cohort Studies Hepatitis B Virus HIV MSM
• Source:
  AIDS. 33(1):145-152
• Pubmed ID:
  30325778
• Pubmed Central ID:
  PMC6279494
• Document Type:
  Journal Article
• Funding:
  R01 DA046203/DA/NIDA NIH HHS/United States ; U01 AI035042/AI/NIAID NIH HHS/United States ; HHSN261201000140C/CA/NCI NIH HHS/United States ; T32 AI007386/AI/NIAID NIH HHS/United States ; HHSN261201000035C/CA/NCI NIH HHS/United States ; U01 AI035041/AI/NIAID NIH HHS/United States ; UM1 AI035043/AI/NIAID NIH HHS/United States ; U58 DP000795/DP/NCCDPHP CDC HHS/United States ; R01 DA030985/DA/NIDA NIH HHS/United States ; HHSN261201000035I/CA/NCI NIH HHS/United States ; UL1 TR000424/TR/NCATS NIH HHS/United States ; HHSN261201000034C/CA/NCI NIH HHS/United States ; U01 AI035043/AI/NIAID NIH HHS/United States ; U58 DP003862/DP/NCCDPHP CDC HHS/United States ; U01 AI035040/AI/NIAID NIH HHS/United States ; U01 AI035039/AI/NIAID NIH HHS/United States
• Volume:
  33
• Issue:
  1
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:7cd591d7ed6945e57590f944e5e013c5d5a8a1f53f293cc4fca6ef0abee5a0de
• Download URL:
  https://stacks.cdc.gov/view/cdc/61235/cdc_61235_DS1.pdf
• File Type:
  [PDF - 343.37 KB ]